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invasive approach. The aim of this study was to assess whether in a real life setting 
performing acute PCI would have an impact on outcomes as length of stay (LOS) and 
mortality in patients hospitalized for acute coronary syndromes in Belgium. 
METHODS: The average length of stay (LOS) and mortality among hospitalized 
patients with acute coronary syndrome were estimated using the longitudinal IMS 
Hospital Disease Database (year 2007), including data on 34.3% of Belgian hospital 
beds. Stays were identiﬁ ed based on ICD-9 coding and split in ST-elevated Myocardial 
infarction (STEMI ICD-9: 410 excluding 410.7), non-STEMI (ICD-9: 410.7-411.89) 
and unstable angina (ICD-9: 411.1-411.8-413.0). Invasive procedures were identiﬁ ed 
with ICD-9 codes corresponding to PCI (36.0). First stays in the calendar year were 
examined. Comparisons were performed using a Wilcoxon non-parametrical test for 
LOS and a Chi-square for mortality rates. RESULTS: In ﬁ rst hospitalizations, 3,420 
STEMI, 2,070 non-STEMI and 954 unstable anginas were retrieved from the database, 
with respectively 1,206, 504 and 28 of them being treated invasively. LOS of patients 
undergoing PCI was signiﬁ cantly lower in STEMI (6.0 vs. 9.5 days; P < 0.001) and 
non-STEMI (5.1 vs. 9.5; P < 0.001). Mortality in patients with PCI was lower in both 
STEMI (3.5% vs. 17.2%; P < 0.001) and non-STEMI (0.8% vs. 6.2%; P < 0.001). 
Although LOS and mortality in non-invasively treated patients were lower in hospitals 
without a cathlab compared to hospitals with a cathlab, both parameters were signiﬁ -
cantly higher compared to PCI treated patients. CONCLUSIONS: Although informa-
tion on the baseline characteristics of the different patients is limited, the ﬁ ndings of 
this observational study seem to support randomized clinical trials. Treatment with 
PCI decreases the LOS and the mortality signiﬁ cantly in patients with a myocardial 
infarction.
PCV25
RISK OF STROKE AND PREVENTATIVE STEPS AMONG PATIENTS 
DIAGNOSED WITH ATRIAL FIBRILLATION IN EUROPE
Gupta S1, Goren A2, Freedman D1
1Kantar Health, Princeton, NJ, USA; 2Kantar Health, New York, NY, USA
OBJECTIVES: This study examined stroke risk and prevention among European 
patients diagnosed with atrial ﬁ brillation (AF). METHODS: Data were extracted from 
the European 2008 National Health and Wellness Survey, an annual Internet survey 
of self-reported health care attitudes and behaviors among 52,524 adults in Germany, 
Spain, Italy, the UK, and France. Stroke risk was assessed with CHADS2, an index 
summing the presence of congestive heart failure, hypertension, age of 75 years+, 
diabetes mellitus, and history of prior stroke or transient ischemic attack (the latter 
weighted twice). Low- (CHADS2 = 0), moderate- (1), and high- (2+) risk patients 
reported on what steps, if any, they took to prevent stroke: low fat or low sodium 
diet, regular exercise, smoking cessation, weight loss, blood pressure or cholesterol 
reduction, and use of baby aspirin, aggrenox, coumadin/warfarin, plavix, or other 
medications. RESULTS: Among 508 respondents diagnosed with AF (EU prevalence 
of 0.97%), 198 (39%) were low, 158 (31.1%) moderate, and 152 (29.9%) high in 
risk for stroke. Signiﬁ cant differences emerged in the use of any preventative steps 
among low- (23.7%), moderate- (35.4%), and high- (57.2%) risk patients, P < 0.05. 
High-risk patients were signiﬁ cantly more likely than the low-risk group to take every 
preventative step except exercise—16.2% (low), 17.7% (moderate), 20.4% (high)—
and aspirin use—11.1% (low), 13.3% (moderate), 15.8% (high). For example, cou-
madin/warfarin use was higher among high- (21.1%) vs. moderate- (8.9%) and 
low-risk (3.0%) patients, P < 0.05. CONCLUSIONS: In the EU, 42.8% of diagnosed 
AF patients at high risk for stroke took no preventative steps, and no signiﬁ cant dif-
ferences emerged between risk groups on regular exercise and aspirin use. Only 1 in 
5 high-risk patients took coumadin/waraﬁ n, while many more could beneﬁ t from 
prophylactic anticoagulation therapy. Higher risk correlated with higher prevention, 
but there remains an unmet need for increased targeted treatment of high-risk AF 
patients.
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WITH HIP OR KNEE REPLACEMENT SURGERY AND OF ITS IMPACT ON 
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OBJECTIVES: Recent clinical trials on the new anti-thrombotic agents have shown 
that the incidence of symptomatic deep venous thrombosis (DVT) and pulmonary 
embolism (PE) in patients undergoing hip or knee replacement ranges between 0.5 
and 2%. This study aimed at assessing the real life incidence of DVT/PE after major 
orthopaedic surgery in Belgian and the impact of these complications on the length 
of stay based on a hospital disease database. METHODS: The incidence of DVT/PE 
and the average length of stay (LOS) among patients hospitalized for hip or knee 
replacement surgery were estimated using the longitudinal IMS Hospital Disease 
Database (year 2007), including data on 34.3% of Belgian hospital beds. Stays were 
searched based on ICD-9-CM codes corresponding to hip replacement (81.51-81.52-
81.53) and knee replacement (81.54-81.55). Occurrence of DVT/PE was identiﬁ ed 
with ICD-9 codes 451.1-451.2-453.4. It was also checked whether selected patients 
were administered low-molecular-weight heparin (LMWH). The impact of a DVT/PE 
complication on LOS was assessed through a Wilcoxon non-parametrical test. 
RESULTS: A total of 9377 stays with hip replacement and 6,978 stays with knee 
replacement were retrieved in the database. More than 99.9% of the patients were 
administered LMWH in both subgroups. The number of stays with a DVT/PE episode 
was respectively equal to 51 and 75 within the 2 subgroups, resulting in an incidence 
of 0.54% in patients with hip replacement and 1.07% in patients with knee replace-
ment. LOS of patients with a DVT/PE episode was more than twice as high after both 
hip (34.2 vs. 15.9 days; P < 0.001) and knee (24.9 vs. 12.0 days; P < 0.001) replace-
ment. CONCLUSIONS: The incidences of symptomatic DVT and PE reported in 
clinical trials could be conﬁ rmed based on this retrospective search. The occurrence 
of DVT/PE doubles LOS in patients undergoing hip or knee surgery.
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SYSTEMATIC REVIEW FROM 1990 TO 2009
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OBJECTIVES: This study aimed at synthesizing population-based studies on preva-
lence of hypertension in Nigeria from 1990 to 2009. METHODS: Cochrane library 
and PubMed were searched for similar reviews using ﬁ lters for systematic review. 
General databases as well as subject-speciﬁ c databases were searched for primary 
studies. Manuscripts of appropriate studies were retrieved. Quality assessment scale 
was developed to assess the retrieved manuscript and only eligible studies were 
selected. Formal meta-analysis was not conducted due to heterogeneity of data. 
RESULTS: A total of 55 abstracts were identiﬁ ed, out of which 10 full manuscripts 
were retrieved and used for systematic review. There was an increasing trend in preva-
lence of hypertension. Hypertension prevalence in rural areas increased from 18.7% 
in 2003 to 22.4% in 2007. In urban areas, it increased from 23.4% in 1997 to 27.1% 
in 2007. In studies that combined both rural and urban populations, prevalence of 
hypertension increased from 14.5% in 1994 to 34.8% in 2003. There was gender 
difference with respect to prevalence of hypertension as males had higher prevalence 
of hypertension compare to females. CONCLUSIONS: Prevalence of hypertension 
seems to be on the increase in Nigeria. There is a need to develop strategies to prevent, 
treat, and control hypertension effectively in Nigeria.
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OBJECTIVES: Current prevalence of cardiovascular risk factors are lacking among 
Asian Indian adults. This study contributes to our knowledge by examining current 
national estimates for hypertension, high cholesterol, diabetes and obesity among 
Asian Indian and white adults aged 20 years and older, by gender and age group. 
METHODS: Cross-sectional observational study design. Analysis of adults 20 years 
and older surveyed in the National Health Interview Surveys (NHIS 2006–2008) 
(Asian Indian, n = 707, white, n = 51,769). RESULTS: The age-standardized preva-
lence of hypertension among Asian Indian adults is 21%, signiﬁ cantly lower than the 
27% prevalence among white adults. At 27%, high cholesterol is equally prevalent in 
both populations. Diabetes is more prevalent among Asian Indian adults (15% vs. 
7%). Asian Indian men have more than twice the rate of diabetes as white men, (17% 
vs.7%), and Asian Indians aged 65 years and older have a higher prevalence of dia-
betes than older, white adults (28% vs. 17%). Obesity rates for Asian Indian adults 
aged 20–39, 40–64, and 65+ are 10%, 16%, and 16%, respectively. Obesity rates for 
white adults aged 20–39, 40–64, and 65+ are 26%, 34%, and 27%, respectively (p 
< 0.0001 for all but 65+ obesity differences). CONCLUSIONS: The age-standardized 
prevalence rate of high cholesterol is similar among Asian Indian and white adults. 
Hypertension rates are lower among Asian Indians. The prevalence of diabetes is 
higher in the Asian Indian population, disproportionately affecting men and older 
adults. Targeted approaches for diabetes disease treatment and reduction are needed.
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OBJECTIVES: To evaluate the prevalence, characteristics, and in-hospital outcomes 
of metabolic syndrome (MS) in acute coronary syndrome (ACS) patients in Oman. 
METHODS: Data were analyzed from 1,392 consecutive patients admitted to 15 
hospitals throughout Oman with the ﬁ nal diagnosis of ACS during May 8, 2006 to 
June 6, 2006 and January 29, 2007 to June 29, 2007, as part of Gulf RACE (Registry 
of Acute Coronary Events). MS was deﬁ ned, as stipulated by the recent ATP-III 
guidelines, as having 3 or more of the following abnormalities: waist circumference 
of ≥94 cm for men and ≥80 cm for women, high triglyceride levels (of ≥150 mg/dL 
(1.7 mmol/L) or drug treatment), low high density lipoprotein cholesterol (HDL-C) 
levels (of <40 mg/dL (1.0 mmol/L) for men and <50 mg/dL (1.3 mmol/L) for females 
or drug treatment), blood pressure (of ≥130 mmHg for systolic and/or ≥85 mmHg for 
diastolic or drug treatment), and blood sugar (of ≥100 mg/dL (≥5.6 mmol/L) or drug 
treatment). RESULTS: The overall prevalence rate of MS in ACS patients in Oman 
was 66% with females being the majority (80% versus 57%; P < 0.001). MS was 
associated with higher median body mass index scores (27 versus 24; P < 0.001), 
diabetics (45% versus 19%; P < 0.001), hyperlipidemia (40% versus 23%; P < 0.001), 
hypertension (62% versus 34%; P < 0.001), renal impairment (9.3% versus 3.4%; P 
< 0.001), killip score >II (13% versus 8%; p = 0.004) and non-ST segment elevation 
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myocardial infarction (78% versus 68%; P < 0.001). Even after multivariate adjust-
ment, MS was still associated with higher risk of in-hospital heart failure (odds ratio 
(OR), 1.37; 95% CI: 1.03–1.81; p = 0.028) and mortality (OR, 4.42; 95% CI: 
1.25–15.5; p = 0.020). CONCLUSIONS: Prevalence of MS in ACS patients in Oman 
is high and seen more in females than in males. Furthermore, MS was associated with 
higher in-hospital heart failure and mortality.
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OBJECTIVES: Despite the availability of the ESC European guidelines on cardiovas-
cular prevention, considerable cardiovascular mortality remains throughout Europe. 
The European Study on Cardiovascular Risk Prevention and Management in Daily 
Practice (EURIKA) (NCT00882336) investigated the prevalence and degree of control 
of main cardiovascular risk factors in primary prevention of cardiovascular disease 
(CVD). METHODS: EURIKA was a cross-sectional study conducted simultaneously 
in 12 European countries (n = 809 primary care and specialist physicians). Patients 
aged ≥50 years who were free of clinical CVD, but had at least one risk factor as 
deﬁ ned by the 2007 European guidelines on cardiovascular prevention, were eligible 
for inclusion. Data recorded included smoking status, body mass index, cholesterol 
levels, blood pressure and presence of diabetes. Cardiovascular risk was assessed by 
Systematic COronary Risk Evaluation (SCORE) methods. Attributable coronary mor-
tality was calculated based on our prevalence estimates together with hazard ratios 
for CVD-related mortality (from the Third National Health and Nutrition Examina-
tion Survey). RESULTS: In total, 7641 patients (mean age: 65 years; 48% male) were 
evaluated. Of those aged <65 years, 27% had a SCORE-based absolute risk of CVD 
of ≥5%. The prevalence of risk factors was 21.3% for current smoking, 71.9% for 
hypertension, 55.4% for dyslipidemia, and 26.6% for diabetes. Control of risk factors 
among patients receiving therapy was 49% (between country range: 40–61%) for 
hypertension, 48% (26–74%) for dyslipidaemia and 40% (26–54%) for diabetes. The 
adjusted excess mortality attributable to risk factors was 17% (14–25%) for current 
smoking, 23% (21–25%) for hypertension, 26% (17–31%) for dyslipidaemia, and 
30% (20–37%) for diabetes. CONCLUSIONS: The prevalence of traditional cardio-
vascular risk factors is high and their control is suboptimal. Traditional risk factors 
such as hypertension, dyslipidaemia and diabetes are responsible for a large fraction 
of the estimated coronary deaths that could be avoided through primary prevention.
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OBJECTIVES: This study aims to determine the degree of blood pressure (BP) control 
and the differences in therapeutic strategies adopted by physicians based on patients’ 
age and/or their functional status. METHODS: Multicenter and cross-sectional study 
that included patients with essential hypertension attending primary or specialist care, 
with at least one year of evolution. The study included 6453 patients, stratiﬁ ed into 
three main groups: a (<65 years) = 2184; B (65–79 years) = 2079; and C (≥80 years) 
= 2079. RESULTS: 51.3% of patients were male and mean (SD) age was 55.1 ± 7.5 
years (group A), 71.4 ± 4.0 (B) and 83.7 ± 3.2 (C). 49.1% of patients were overweight. 
Mean systolic BP values were 141.3 ± 15.6 (A), 142.0 ± 16.3 (B) and 142.3 ± 16.8 
(C) mmHg, and mean diastolic BP values were 84.5 ± 10.1 (A), 81.5 ± 10.5, 79.9 ± 
11.2 (C) mmHg. 33.5% of patients had type 2 diabetes mellitus and 59.1% dyslipid-
emia. The existence of previous cardiovascular (CVD) or renal disease has been 
established in 38.9% of cases. The prevalence of CVD was 22.6% (A), 39.1% (B) and 
55.9% (C). Target organ damage (TOD) was 26.7% (A), 40.8% (B) and 57.8% (C). 
The Barthel index that measures a person’s daily functioning reﬂ ected that the oldest 
group had a signiﬁ cantly higher level of moderate or severe dependence (P < 0.0001). 
Patients with controlled BP were 29.4% (A), 25.5% (B) and 23.7% (C) (P < 0.0001). 
Clinical inertia—the failure to intensify therapy in patients who do not achieve the 
clinical objectives—reached 60.3% (A), 61.7% (B) and 66.2% (C) (p = 0.0002), 
respectively. Global treatment compliance was 94.3%, and the difﬁ culty for taking 
the medication signiﬁ cantly increased with patients’ age (P < 0.0001). CONCLU-
SIONS: Older hypertensive patients have a poorer BP control but an increased clinical 
inertia. These patients have higher prevalence of TOD and CVD, worse functional 
status and worse treatment compliance. 
CARDIOVASCULAR DISORDERS – Cost Studies
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OBJECTIVES: The self-expandable paclitaxel DES represents a major development in 
endovascular treatments for lower limb PAD. Clinical data show improved clinical 
outcomes compared to bare metal stents (BMS). This budget impact analysis assessed 
the impact of introducing reimbursement for a paclitaxel DES in France. METHODS: 
An Excel-based model was developed to estimate the impact of a transition from BMS 
to DES over a 5-year horizon (15% in 2011 to 35% in 2015). Hospital episode sta-
tistics were used to estimate the 2011–2015 patient population. The analysis was 
conducted from the payer perspective and only direct costs of procedures were con-
sidered, based on GHM 2009 tariffs (stenting and revascularization) and LPPR tariffs 
(BMS and grafts). The main outcome was target lesion revascularization (TLR) in the 
superﬁ cial femoral artery (SFA) after primary stent placement: angioplasty, re-stenting, 
or bypass surgery. TLR rates were based on the paclitaxel drug-eluting SFA stent 
registry study and on BMS TLR rates reported in the literature (Years 1 and 2: 6% 
and 9% for the DES; 16% and 22% for average BMS) and extrapolated for years 3 
to 5. Net budget impact was expressed as the difference in cost between the scenario 
where the DES is progressively adopted versus the status quo (patients treated with 
BMS only). RESULTS: The base-case results show an incremental cost of c278,526 
in year 1, which is more than offset by increasing cost savings in all subsequent years 
(year 2: −c35,901; year 5: −c510,025), resulting in a cumulative 5-year net budget 
impact of −c727,649. One-way sensitivity analyses on key inputs continued to show 
cumulative 5-year cost savings. CONCLUSIONS: Reimbursement and consequent 
adoption of the paclitaxel DES would result in cost savings for the French health care 
payer, despite requiring an initial investment. This is due to savings associated with 
fewer SFA revascularization events after the primary intervention.
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition and treatment 
often involves a major operation. For a subgroup of patients medical management 
(MM) is the only treatment option due to procedural risk. A transcatheter aortic valve 
implantation device “CoreValve,” is less invasive and allows for the implantation of 
a replacement valve in this patient group. However, CoreValve is more expensive than 
MM and introducing this technology into routine care would lead to an increase in 
National Health Service (NHS) spending. We estimated this budgetary impact using 
existing economic models. METHODS: In an Excel based Markov model CoreValve 
was compared to MM for inoperable patients. Parameters were derived from pub-
lished literature. Costs were taken from the most recent published sources. Decrements 
were applied to age-speciﬁ c EQ-5D population norms to generate QALYs. Incidence 
estimates were derived from information in a large national database. Projected ﬁ ve 
year uptake rates were provided by Medtronic. The outputs from the economic model 
were used for all relevant parameters. Case mix estimates were elicited from a clinical 
advisory board. RESULTS: Across all patients, the estimated incidence rate of AS was 
165 per million, 40% of these patients were assumed to be inoperable, 66 per million. 
The uptake rate of CoreValve in the inoperable group rose linearly from 0% to 50% 
over 5 years. When all inoperable patients were treated with MM the total budgetary 
cost was £13,454,000. When 50% of patients are treated with CoreValve and 50% 
with MM, the total budgetary cost increases to £49,706,000. Thus, the total burden 
to the NHS of 50% of inoperable patients receiving CoreValve would be £36,251,000. 
With a more optimistic ﬁ ve year uptake rate (75%) this increases to £54,852,000. 
CONCLUSIONS: Introducing CoreValve would result in an additional £36,251,000 
being spent by the UK NHS.
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OBJECTIVES: To calculate and compare costs of primary treatment of hypertension 
with candesartan/hydrochlorothiazide (HCT) or losartan/HCT in the Mexican Social 
Security Institute (IMSS). METHODS: An adaptation from Kjeldsen observational 
study of 14,100 patients diagnosed with hypertension and the costs’ sub analysis of 
Henriksson was made to have an approximation of incurred costs by IMSS when using 
candesartan/HCT or losartan/HCT in the primary hypertension treatment and its 
impact in reducing related cardiovascular events. First assumption for adaptation was 
to use only costs of combined therapies with HCT since monotherapies are not 
included in the IMSS formulary. Hospitalizations, laboratory tests and physician visits 
resource consumption reported by Kjeldsen were multiplied by IMSS 2010 unit costs. 
